MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES: AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA
| Autor: | Bullement, A., Amin, A., Stapelkamp, C., Willis, A., Lilley, C., Hatswell, A.J., Pescott, C., Bharmal, M. |
|---|---|
| Zdroj: | In Value in Health October 2018 21 Supplement 3:S11-S11 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect